Andrew Fisher Joins Verona Pharma as General Counsel
04 Marzo 2024 - 8:00AM
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the
“Company”), announces Mr. Andrew Fisher has today joined the
Company as General Counsel, and member of the Executive Management
Team.
Mr. Fisher is an accomplished lawyer with more
than 25 years of experience in the life sciences industry. He
brings a wealth of legal and strategic expertise supporting global,
pre-clinical and clinical development, manufacturing and
commercialization including launching four pulmonary therapies.
Most recently, he founded and led a consulting practice focused on
providing strategic advice to start-up companies. Previously, from
2001 until 2018, he was an early team member at United Therapeutics
Corporation where he served for 17 years holding roles of
increasing responsibility including Executive Vice President, Chief
Strategy Officer and Deputy General Counsel while leading
successful patent defense strategy. During this period, the company
grew from an early-stage business to a company with 850 employees,
a market capitalization of $4.7 billion and five marketed products.
He has a JD from George Washington University and a BA from
University of Michigan.
“We are delighted to welcome Andy to Verona,”
said David Zaccardelli, Pharm. D., President and Chief Executive
Officer. “His broad expertise and leadership spanning all areas of
legal affairs in commercial life sciences and intellectual property
portfolio management and strategy will be highly valuable as we
finalize preparations for the planned US commercialization of
ensifentrine, if approved, later this year.”
Verona Pharma also announces that Ms. Claire
Poll is retiring as General Counsel, effective March 4, 2024.
Dr. Zaccardelli added: “We would like to thank
Claire for her leadership and recognise her significant
contributions to Verona Pharma’s successful development since its
inception. During this time, she played a key role in the Company’s
growth by providing guidance through our NASDAQ listing, several
financings and the progression of our novel product candidate,
ensifentrine, through clinical trials into review for potential US
approval.”
For further information please contact:
Verona Pharma plc |
US Tel: +1-833-417-0262UK Tel: +44 (0)203 283 4200 |
Victoria Stewart, Senior Director of Investor Relations and
Communications |
IR@veronapharma.com |
Argot PartnersUS Investor Enquiries |
Tel: +1-212-600-1902verona@argotpartners.com |
Ten Bridge CommunicationsInternational / US Media
Enquiries |
Tel: +1-312-523-5016tbcverona@tenbridgecommunications.com |
Leslie Humbel |
|
About Verona Pharma
Verona Pharma is a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for the treatment of chronic respiratory
diseases with significant unmet medical needs. If successfully
developed and approved, Verona Pharma’s product candidate,
ensifentrine, has the potential to become the first inhaled
non-steroidal therapy for the treatment of respiratory diseases
that combines bronchodilator and anti-inflammatory activities in
one molecule. The Company has evaluated nebulized ensifentrine in
its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel
inHAled Nebulized COPD thErapy”) for COPD maintenance treatment.
Ensifentrine met the primary endpoint in both ENHANCE-1 and
ENHANCE-2 trials demonstrating statistically significant and
clinically meaningful improvements in lung function. In addition,
ensifentrine substantially reduced the rate and risk of COPD
exacerbations in pooled analysis from ENHANCE-1 and ENHANCE-2. In
the third quarter of 2023, the US Food and Drug Administration
accepted for review the Company’s NDA for ensifentrine for the
maintenance treatment of patients with COPD and assigned a PDUFA
target action date of June 26, 2024. Two additional
formulations of ensifentrine have been evaluated in Phase 2 trials
for the treatment of COPD: dry powder inhaler (“DPI”) and
pressurized metered-dose inhaler (“pMDI”). Ensifentrine has
potential applications in cystic fibrosis, non-cystic fibrosis
bronchiectasis, asthma and other respiratory diseases. For more
information, please visit www.veronapharma.com
Forward-Looking Statements
This press release contains forward-looking
statements. All statements contained in this press release that do
not relate to matters of historical fact should be considered
forward-looking statements. These forward-looking statements are
based on management's current expectations. These statements are
neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause our
actual results, performance, or achievements to be materially
different from our expectations expressed or implied by the
forward-looking statements. Any such forward-looking statements
represent management's estimates as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
Grafico Azioni Verona Pharma (NASDAQ:VRNA)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Verona Pharma (NASDAQ:VRNA)
Storico
Da Ott 2023 a Ott 2024